GSK-102

N/A

Report date: 2025/01/26 16:08:50
NME

Base Information

Drug NameGSK-102
Drug Alias NameRIPK2 PROTACS (GSK)RIPK2 degraders (GSK)serine/threonine-protein kinase 2 degraders (GSK)GSK-102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUbiquitin-protein ligases modulatorsSerine/threonine-protein kinase RIPK2 modulatorsProteasome stimulants
TargetsProteasomeUbiquitin-protein ligasesSerine/threonine-protein kinase RIPK2
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A